Evidence map›Paper›PMID 37274769›Full record

ArticleChina CDC weekly2023

Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease - Hebei Province, China, November 2018 to November 2020.

Yan Li, Pingshu Zhang, Zhijie An, Ying Ma, Yamin Wang, Liye Wang, Yunqiu Liu, Xiaodong Yuan, Keli Li, Zundong Yin and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Prevalence ofHuman vaccines & immunotherapeutics · 2024
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yan LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Pingshu ZhangKailuan General Hospital, Tangshan City, Hebei Province, China.
Zhijie AnNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Ying MaKailuan General Hospital, Tangshan City, Hebei Province, China.
Yamin WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Liye WangKailuan General Hospital, Tangshan City, Hebei Province, China.
Yunqiu LiuKailuan General Hospital, Tangshan City, Hebei Province, China.
Xiaodong YuanKailuan General Hospital, Tangshan City, Hebei Province, China.
Keli LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Huaqing WangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chinese Center For Disease Control and Prevention · CNKailuan General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known on this topic?: Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden. What is added by this report?: This study demonstrated the economic burden of COPD exacerbations, pneumonia, and hospitalization in COPD patients in China is substantial. Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately or together, were significantly associated with decreased economic burden. What are the implications for public health practice?: Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.

Indexed as

Acute ExacerbationsCOPD patientsEconomic burden

Identifiers

PMID37274769
PMCPMC10236643
OpenAlexW4379376617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.